Oculoplastics News

A split-face comparison found no difference between onabotulinumtoxinA and prabotulinumtoxinA for the treatment of glabellar frown lines, according to a study presented at the Women in Ophthalmology Summer Symposium.

Teprotumumab was approved for the treatment of thyroid eye disease in January 2020. As real-world experience with teprotumumab increases, several clinical reports describing patient responses, safety and effectiveness are now appearing.

Not everyone can agree on what to call thyroid eye disease.

WAILEA, Hawaii — In this video from Hawaiian Eye 2021, Roger A. Dailey, MD, discusses outcomes in patients treated for thyroid eye disease with traditional methods and teprotumumab.

WAILEA, Hawaii — In this video from Hawaiian Eye 2021, Wendy Lee, MD, summarizes her presentation on identifying and dealing with eyelid lesions.

WAILEA, Hawaii — In this video at Hawaiian Eye, Andrew R. Harrison, MD, shares his surgical pearls for entropion and ectropion and lower eyelid malposition.

WAILEA, Hawaii — In patients with traumatic periorbital and orbital injuries, airway, breathing and circulation – the ABCs – need to be addressed first, before addressing ocular trauma.

WAILEA, Hawaii — Adverse reactions from soft tissue augmentation are usually mild, but oculoplastic specialists should be aware of potentially vision-threatening vascular compromise, according to a speaker at Hawaiian Eye 2021.

WAILEA, Hawaii — In this video from Hawaiian Eye, Wendy W. Lee, MD, and Roger A. Dailey, MD, discuss the latest information surrounding diagnosis and management of thyroid eye disease.

Most adults with thyroid eye disease receiving an infusion of teprotumumab every 3 weeks for a 24-week period had a reduction of at least 2 mm in proptosis, with a long-term response observed in 67% of participants, according to study data.